Historically, the outcomes for individuals with triple-class refractory and penta-drug refractory
multiple myeloma (MM) have been poor because of a dearth of effective treatment options …

Chimeric antigen receptor T-cell (CAR T-cell) therapy has revolutionized the treatment of
hematologic malignancies in patients with relapsed or refractory disease without other …

The therapeutic landscape of multiple myeloma (MM) has benefited from an emergence of
novel therapies over the last decade. By inducing T-cell kill of target cancer cells, chimeric …

There has been an increase in volume as well as an improvement in overall survival (OS)
after hematopoietic cell transplantation (HCT) for hematologic disorders. It is unknown if …

Adoptive transfer of naturally occurring or genetically engineered T cells is an effective
treatment for certain haematological malignancies, such as non-Hodgkin lymphoma and …

Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapeutic approach
in the treatment of multiple myeloma, and the recent approval of the first two CAR T-cell …

Diffuse large B cell lymphoma (DLBCL) is the most prevalent subtype of non-Hodgkin
lymphoma. Although outcomes to frontline therapy are encouraging, patients who are …

Although chimeric antigen receptor (CAR) T cell therapy (CAR-T) has altered the treatment
landscape for relapsed/refractory B cell malignancies and multiple myeloma, only a minority …

Cancer outcomes with chemotherapy are inferior in patients of minority racial/ethnic groups
and those with obesity. Chimeric antigen receptor (CAR) T-cell therapy has transformed …

Many studies have documented racial, socioeconomic, geographic, and other disparities for
United States (US) patients with multiple myeloma pertaining to diagnosis and frontline …